WallStSmart
PHG

Koninklijke Philips NV ADR

NYSE: PHG · HEALTHCARE · MEDICAL DEVICES

$25.58
-5.68% today

Updated 2026-04-29

Market cap
$24.33B
P/E ratio
23.47
P/S ratio
1.37x
EPS (TTM)
$1.09
Dividend yield
3.96%
52W range
$22 – $33
Volume
1.0M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Koninklijke Philips NV ADR (PHG) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$25.58
Consensus
$26,230.00
+102441.05%
2030 Target
$279.23
+991.59%
DCF
$33.33
+3.78% MoS
23 analysts:
3 Buy19 Hold1 Sell

Management guidance

At the Capital Markets Day (February 2026), Philips management announced 2026-2028 targets with accelerating growth. CEO Roy Jakobs indicated the turnaround is real with margin expansion and solid cash flow. While specific revenue targets were not explicitly disclosed in the available documents, management guided for growth acceleration beyond the 2.79% FY2026 and 4.38% FY2027 consensus estimates, suggesting confidence in mid-to-high single-digit growth trajectory.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$466.29
$22.3B Rev × 20x P/S
Base case (2030)
$279.23
$22.3B Rev × 12x P/S
Bear case (2030)
$187.06
$22.3B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$18.2B$18.0B$17.8B$18.3B$19.1B$20.1B$21.1B$22.3B
Revenue growth—-0.8%-1.0%2.8%4.4%4.8%5.4%5.4%
EPS$1.24$1.39$1.64$1.53$1.73$1.92$2.15$2.39
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$230.44$238.57$252.12$265.68$279.23

Catalysts & risks

Growth catalysts
+ FDA clearance for AI-powered EchoNavigator R5.0 and structural heart solutions driving interventional cardiology segment growth
+ IntraSight Plus coronary intervention platform reducing system time by 47% - major competitive advantage in interventional labs
+ Cloud-enabled digital pathology (IntelliSite on HealthSuite) capturing digital diagnostics TAM expansion across global healthcare systems
+ Leadership stability with CEO Roy Jakobs re-appointment through 2028+ providing continuity on turnaround strategy
+ Patent leadership position (1,289 European patent applications in 2025, #1 medtech) supporting premium product cycle innovation
+ Platform-based care intelligence integration connecting patient monitoring with diagnostics - recurring SaaS revenue model expansion
Key risks
- Historical revenue volatility and stagnation (5-year CAGR only 0.6%, negative growth 2024-2025) raises execution risk on acceleration targets
- Regulatory and litigation exposure across medical devices - FDA clearances required for product launches and portfolio expansion
- Geopolitical tensions and tariff headwinds acknowledged by management as offsetting factors for 2026+ growth
- Competitive intensity from larger peers (GE HealthCare $20.6B revenue, larger scale) and specialized innovators in AI diagnostics
- Analyst consensus remains cautious - majority Hold ratings despite CEO visibility suggests lingering credibility gap on turnaround pace
- Cybersecurity and data privacy risks inherent to connected care platforms and cloud-based pathology solutions

Methodology

Koninklijke Philips NV ADR's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 23 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.